AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23182627
Drug: Tivantinib (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (360 mg twice‐daily)
Trial: 23182627
Drug: Tivantinib (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib (240 mg twice‐daily)
Trial: 23182627
Drug: Tivantinib 360
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 360 mg
Trial: 23182627
Drug: Tivantinib 240
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 240 mg
Trial: 21817157
Drug: Simultaneous intratympanic
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous intratympanic dexamethasone with systemic steroids
Trial: 21817157
Drug: Subsequent intratympanic
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subsequent intratympanic dexamethasone given 7 days after systemic treatment
Trial: 21817157
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone treatment
Trial: 19118304
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg per day for 3 years
Trial: 19118304
Drug: Alendronate (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (various doses)
Trial: 19118304
Drug: Alendronate treatment
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate treatment discontinued for 1 year
Trial: 7800216
Drug: Cyclosporin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (12 mg/kg)
Trial: 8301102
Drug: Cyclosporin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (30 mg/kg)
Trial: 24831979
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day, orally)
Trial: 24831979
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2, intravenously, every 21 days, or docetaxel 75 mg/m2, intravenously, every 21 days)
Trial: 8746044
Drug: Short chain
RxNorm normalized name: Short chain acyl-CoA dehydrogenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short chain fatty acids enema (acetate: 60 mmol/L; propionate: 30 mmol/L; n-butyrate: 40 mmol/L) administered twice a day for 14 days (group 1; n = 7)
Trial: 2796619
Drug: Tetracaine 10
RxNorm normalized name: tetracaine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 15 microgram clonidine (Gr.2)
Trial: 2796619
Drug: Tetracaine 10
RxNorm normalized name: tetracaine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 30 microgram clonidine (Gr.3)
Trial: 2796619
Drug: Tetracaine 10
RxNorm normalized name: tetracaine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL + 45 microgram clonidine (Gr.4)
Trial: 2796619
Drug: Tetracaine 10
RxNorm normalized name: tetracaine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 10 mg in 10% glucose solution 2 mL (Control Group)
Trial: 31761541
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) with a dose prescription of 40 Gy in 5 fractions.
Trial: 31761541
Drug: Standardized dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized dose constraints and clinical target volume delineation for SBRT.
Trial: 23349295
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in a specialised out‐patient mood disorder clinic
Trial: 23349295
Drug: Standard out-patient
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard out-patient treatment
Trial: 19487105
Drug: Salmon (150g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon (150g three times per week, resulting in a daily consumption of 2.1g of omega-3 long-chain polyunsaturated fatty acids)
Trial: 19487105
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (1.3g of omega-3 long-chain polyunsaturated fatty acids per day)
Trial: 19487105
Drug: Cod (150g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod (150g three times per week, resulting in a daily consumption of 0.3g of omega-3 long-chain polyunsaturated fatty acids)
Trial: 8698447
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (10 to 40 mg/d), with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Trial: 1470824
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone administered intra‐vaginally (600 mg/d)
Trial: 1470824
Drug: Progesterone in
RxNorm normalized name: Progesterone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone in solution in oil (50 mg/day) administered by intramuscular injection
Trial: 6362694
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine with adrenaline 5 micrograms ml‐1
Trial: 6362694
Drug: 1.5% etidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% etidocaine with adrenaline 5 micrograms ml‐1
Trial: 26657213
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy sessions (placebo control)
Trial: 24674576
Drug: Bifocal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifocal treatment (+1.75 add) during the 3-year period in childhood
Trial: 24674576
Drug: Watching television
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watching television <3 hours daily
Trial: 22527106
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus patient support program
Trial: 20357369
Drug: 0.25 microg
RxNorm normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 microg 1,25(OH)(2)D(3) daily for 9 months
Trial: 18556967
Drug: Compensated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compensated Insulin Resistance (CIR)
Trial: 18556967
Drug: Decompensated Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decompensated Insulin Resistance (DIR)
Trial: 18556967
Drug: Normal Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Insulin Sensitivity (NIS)
Trial: 25603459
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/d)
Trial: 15883215
Drug: Glimepiride (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2.7 mg/d)
Trial: 11817924
Drug: Demographic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographic and psychosocial factors (e.g., race, academic rank, depressive symptomatology, self-reported value of health, appearance, and achievement, parenting style)
Trial: 8963917
Drug: Daily ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of 30 mg of beta-carotene supplements
Trial: 1704989
Drug: Metoprolol (M)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (M) 100 mg daily
Trial: 1704989
Drug: Cilazapril (C)
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (C) 2.5 mg daily
Trial: 23326865
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg)
Trial: 23420622
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for personality disorders (CBTpd) plus Treatment as Usual
Trial: 21848799
Drug: Esomeprazole (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (7 weeks treatment)
Trial: 21848799
Drug: Placebo (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (7 weeks treatment)
Trial: 20008236
Drug: Emerging new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging new treatment modalities under investigation for relapsed classical Hodgkin lymphoma
Trial: 16973256
Drug: Gosereline (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gosereline (3.6 mg subcutaneous injection monthly)
Trial: 11438317
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg daily per os)
Trial: 11440901
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Trial: 11440901
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose infusion at 6 mg x kg(‐1) x min(‐1) for 180 min
Trial: 11440901
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of id and iv glucose infusion
Trial: 8000630
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac sodium (Voltarol; Ciba‐Geigy)
Trial: 30663184
Drug: Clotrimazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (100 mg vaginal tablet, once daily for 7 days)
Trial: 30663184
Drug: Salvia officinalis
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia officinalis (400 mg vaginal tablet, once daily for 7 days)
Trial: 30663184
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Salvia officinalis and Clotrimazole (once daily for 7 days)
Trial: 17907482
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride solution (Nupro Neutral)
Trial: 10943871
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate, cyclosporin A, and corticosteroids)
Trial: 2461826
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of adenosine 5'-monophosphate (AMP) at the provocation concentration required to produce a 20% fall in FEV1 (PC20)
Trial: 2461826
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 0.9% (w/v) sodium chloride placebo
Trial: 2461826
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of the PC20 allergen
Trial: 25641932
Drug: Dry bean
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry bean enriched diet (250 g/day) for 4 weeks
Trial: 25641932
Drug: Self-reported high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported high dry bean intake (≥42 g/day)
Trial: 25641932
Drug: Self-reported low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported low dry bean consumption (<8 g/day)
Trial: 19358978
Drug: Chronotherapeutic augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronotherapeutic augmentation (CAT; Sleep Deprivation + Bright Light + Sleep Phase Advance)
Trial: 19358978
Drug: Medication-only (MED)
RxNorm normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-only (MED) group
Trial: 11716099
Drug: Paromomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin plus methylbenzethonium chloride ointment applied twice a day for 20 days
Trial: 11716099
Drug: Paromomycin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paromomycin plus methylbenzethonium chloride ointment
Trial: 30648920
Drug: Mobile wellness
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile wellness intervention with Fitbit, daily motivational text messaging, and biweekly counseling for 12 weeks
Trial: 7595905
Drug: Losartan monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan monotherapy
Trial: 9577009
Drug: Tolperisone HCL
RxNorm normalized name: tolperisone HCl
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone HCL (Mydocalm) 150 mg twice daily for 12 weeks
Trial: 8449072
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 to 20 mg given three times a day)
Trial: 27284930
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (MCP) 10 mg orally
Trial: 24752831
Drug: Hyzetimibe (HS-25)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyzetimibe (HS-25) 10 mg once daily for 10 days
Trial: 24752831
Drug: Hyzetimibe (HS-25)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyzetimibe (HS-25) 5, 10, and 20 mg (multiple ascending doses)
Trial: 24752831
Drug: Hyzetimibe (HS-25)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyzetimibe (HS-25) 1, 3, 5, 10, 20, and 30 mg (single ascending doses)
Trial: 22345094
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily added to losartan 100 mg once daily plus optimal antihypertensive therapy
Trial: 22345094
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to losartan 100 mg once daily plus optimal antihypertensive therapy
Trial: 11923490
Drug: Undiluted smallpox
RxNorm normalized name: Smallpox vaccine
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undiluted smallpox vaccine (10^8.1 pfu/ml)
Trial: 11923490
Drug: 1:5 diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:5 diluted smallpox vaccine (10^7.2 pfu/ml)
Trial: 11923490
Drug: 1:10 diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:10 diluted smallpox vaccine (10^7.0 pfu/ml)
Trial: 11923490
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (undiluted and diluted vaccines)
Trial: 6209832
Drug: Hemodilution therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodilution therapy
Trial: 126848
Drug: Azapropazone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azapropazone (300 mg, 4-times daily)
Trial: 126848
Drug: Ketoprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (50 mg, 4-times daily)
Trial: 20179636
Drug: Oral beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beclomethasone dipropionate (BDP) 5 mg/day for 8 weeks
Trial: 20179636
Drug: Oral 5-aminosalicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-aminosalicylate (5‐ASA) 80 mg/kg/day
Trial: 17394636
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and activation program (EAP) administered by trained GPs.
Trial: 17394636
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) administered by GPs.
Trial: 7836337
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg once daily, titrated to a maximum of 200 mg)
Trial: 30729333
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D vaginal suppositories
Trial: 30729333
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E vaginal suppositories
Trial: 23824645
Drug: capecitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capecitabine (1,000 mg/m2 twice daily, day 1-day 14)
Trial: 368299
Drug: Dexamethasone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.3 mg/kg at admission and a similar dose 2 hours later)
Trial: 11095456
Drug: Oxandrolone treatment
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxandrolone treatment
Trial: 19589901
Drug: High intermittent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intermittent dose of liposomal amphotericin B (10 mg kg(‐1) on day 1, 5 mg kg(‐1) on days 3 and 6)
Trial: 19589901
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily dose of liposomal amphotericin B (3 mg kg(‐1) per day for 14 days)
Trial: 19589901
Drug: High intermittent
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intermittent dose of liposomal amphotericin B
Trial: 19589901
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily dose of liposomal amphotericin B
Trial: 17116219
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) 1000 mg (500 mg bid.) on the first treatment day, increased to 2000 mg (1000 mg bid.) from the second day onward.
Trial: 15589082
Drug: Self-care management
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care management strategies including prescribed medications for pain management (54.21% of participants used this strategy).
Trial: 11733289
Drug: BiPAP ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP ventilation plus standard treatment
Trial: 11733289
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment alone (non-BiPAP)
Trial: 9164221
Drug: Higher-dose chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose chemotherapy regimen with rhGM-CSF (cyclophosphamide 1,800 mg/m2, 4'-epidoxorubicin 60 mg/m2, etoposide 330 mg/m2, cisplatin 120 mg/m2, plus rhGM-CSF 5 micrograms/kg daily for 10 days)
Trial: 9164221
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy regimen (cyclophosphamide 1,200 mg/m2, 4'-epidoxorubicin 40 mg/m2, etoposide 225 mg/m2, cisplatin 100 mg/m2)
Trial: 9164221
Drug: Higher-dose plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose plus rhGM-CSF group
Trial: 2221511
Drug: Chloropromazine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloropromazine 12.5 mg IV (max 37.5 mg)
Trial: 2221511
Drug: Dihydroergotamine 1
RxNorm normalized name: DIHYDROERGOTAMINE 1MG/ML INJ AMP 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 1 mg IV (repeated after 30 minutes if inadequate response)
Trial: 2221511
Drug: Lidocaine 50
RxNorm normalized name: lidocaine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 50 mg IV (max total dose of 150 mg)
Trial: 589919
Drug: Chocolate-Sorbitol preparation
RxNorm normalized name: chocolate hind preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chocolate-Sorbitol preparation
Trial: 589919
Drug: 46 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 46 g of milk chocolate
Trial: 589919
Drug: 26 g
RxNorm normalized name: Sunmark Lancet Thin 26 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 g of milk chocolate
Trial: 30332895
Drug: Memory Work
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Memory Work Therapy
Trial: 15685825
Drug: Gemcitabine in
RxNorm normalized name: gemcitabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine in combination with paclitaxel
Trial: 11723016
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg/d) for 7 days
Trial: 11723016
Drug: Pl(A2) carriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pl(A2) carriers (no aspirin effect)
Trial: 11723016
Drug: Pl(A1A1) subjects
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pl(A1A1) subjects (after aspirin ingestion)
Trial: 11723016
Drug: Pl(A2) carriers
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pl(A2) carriers (after aspirin ingestion)
Trial: 9220211
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (200 mg once daily)
Trial: 9220211
Drug: Clotrimazole troches
RxNorm normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole troches (10 mg five times daily)
Trial: 3552007
Drug: Intermittent positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent positive pressure ventilation (IPPV) with nitrous oxide in oxygen facilitated by atracurium 0.5 mg kg‐1